Shilpa Medicare
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Shilpa Medicare's recent management commentary highlights a strategic pivot towards high-margin specialty products, particularly in biologics and biosimilars, which are expected to drive significant revenue growth. The company is leveraging its advanced R&D capabilities and expanding its contract development and manufacturing organization (CDMO) business, benefiting from the global trend of outsourcing complex manufacturing to India. Vista's financial outlook reflects a moderate revenue growth trajectory, with expectations of improving margins as the company scales its operations and enhances profitability. The projected 15% CAGR in revenue from FY25 to FY28, supported by a diversified product pipeline and the commissioning of new facilities, aligns with Vista's valuation assessment, which indicates fair value. However, potential headwinds include regulatory risks and competitive pressures in the biologics market, which could impact execution. The macro environment remains supportive, with stable inflation and favorable liquidity conditions, further enhancing Shilpa's growth prospects. Over the next 12-24 months, key opportunities lie in the successful launch of new products and the expansion of the CDMO segment, while watchpoints include regulatory challenges and the need for effective scaling of operations
Why We Like This Stock
- Strategic focus on high-margin biologics and biosimilars expected to drive revenue growth
- Strong projected CAGR of 15% in revenue from FY25 to FY28, supported by a diversified product pipeline
- Favorable macroeconomic conditions and a robust balance sheet enhance growth prospects
Things To Watch Out For
- Regulatory risks and execution challenges in scaling biologics and CDMO segments could hinder growth
- Competitive pressures in the biologics and GLP-1 markets may impact market share
- Slowing revenue growth relative to historical performance raises concerns about sustainability
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,146 | 1,281 | 1,539 | 1,807 | 2,030 |
| Profit Before Tax (Cr.) | 47 | 146 | 283 | 414 | 442 |
| PBT Margin | 4.1% | 11.4% | 1837.8% | 22.9% | 21.8% |
| Net Profit (Cr.) | 8 | 59 | 239 | 348 | 371 |
| Earnings Per Share | 0.4 | 3.0 | 12.2 | 17.8 | 19.0 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Ventura | ▲ Buy | 452 | 07-Apr-2026 |
Company Overview
Show Company Profile
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. It also provides nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate. In addition, the company offers intermediates; peptides; biopolymers; biologics; contract development and manufacturing services; and formulations, such as tablets, capsules, liquid injections, dry powder injectable products, oral dissolving films, transdermal patches. Further, it is involved in the manufacture of specialized oncology formulations; and wind power generation activities. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.